RPS11B Antibody

What is RPS11 and why is it a target for antibody development?

RPS11 (Ribosomal Protein S11) is a member of the ribosomal protein family that has gained significant research interest due to its overexpression in diverse malignancies and correlation with tumor recurrence. The development of specific antibodies against RPS11 enables researchers to investigate its expression patterns and potential prognostic value in various cancer types, particularly hepatocellular carcinoma (HCC) . RPS11 antibodies allow for protein detection and quantification in both native tissues and experimental systems, providing valuable insights into the protein's role in pathological processes.

What are the primary research applications for RPS11 antibodies?

RPS11 antibodies have several important research applications:

• Immunohistochemistry (IHC) for detection of RPS11 expression in tissue sections

• Western blotting for protein quantification in cell and tissue lysates

• Immunocytochemistry/immunofluorescence (ICC/IF) for cellular localization studies

• Flow cytometry (FC) for quantifying RPS11 expression in individual cells

These applications are particularly valuable in cancer research, where RPS11 antibodies can help determine expression levels that correlate with clinical outcomes . For instance, in HCC research, RPS11 antibodies enable the classification of patients into high and low expression groups, which has prognostic implications.

How specific are RPS11 antibodies compared to antibodies against other ribosomal proteins?

Specificity is a critical consideration when working with ribosomal protein antibodies. Modern recombinant RPS11 antibodies offer high specificity for RPS11 without cross-reactivity to other ribosomal proteins . This specificity is essential because ribosomal proteins share structural similarities. When selecting an RPS11 antibody, researchers should look for validation data demonstrating specificity, such as Western blot results showing a single band at the expected molecular weight and absence of signal in negative control samples. The specificity challenge is similar to that faced with other ribosomal protein antibodies, such as those developed against RPS4Y1, where high sequence homology (93% identity with RPS4X) required careful epitope selection .

What is the optimal immunohistochemistry protocol for using RPS11 antibodies in tissue sections?

For optimal immunohistochemistry results with RPS11 antibodies, the following protocol has been validated in HCC research:

• Prepare formalin-fixed paraffin-embedded tissue sections (4 μm thickness)

• Deparaffinize and rehydrate the sections through graded alcohols

• Perform antigen retrieval using citrate buffer (pH 6.0)

• Block endogenous peroxidase activity with 3% H₂O₂ solution for 15 minutes at room temperature

• Incubate with primary RPS11 antibody (1:100 dilution) overnight at 4°C

• Apply horseradish peroxidase (HRP)-conjugated secondary antibody for 45 minutes at 37°C

• Develop signal using diaminobenzidine (DAB) solution

• Counterstain nuclei with Harris' Hematoxylin

• Dehydrate, clear, and mount the sections

Assessment should employ the H-score method, which multiplies staining intensity (negative: 0, weak: 1, moderate: 2, strong: 3) by staining extent (0-100%) to generate a comprehensive score.

How should RPS11 antibody staining be normalized in protein microarray experiments?

Normalization is critical for accurate interpretation of RPS11 antibody signals in protein microarray experiments. Based on research on reverse phase protein microarray (RPMA) normalization, several approaches can be considered:

• Single-stranded DNA (ssDNA) normalization: ssDNA has been demonstrated to be proportional to total non-red blood cell content and serves as a suitable normalization parameter for RPMA, including for ribosomal protein detection . This method requires:

  • Eliminating alkaline pre-treatment of the microarray prior to immunostaining

  • Including ssDNA positive controls and RNA negative controls

  • Probing a parallel array with anti-ssDNA antibody

• Housekeeping protein normalization: When normalizing RPS11 signals, consider using established housekeeping proteins such as:

  • Glyceraldehyde 3-phosphate dehydrogenase

  • α/β-tubulin

  • β-actin

For samples with potential blood contamination, special consideration should be given to RBC protein content that might influence normalization .

What controls should be included when validating a new lot of RPS11 antibody?

When validating a new lot of RPS11 antibody, researchers should include the following controls:

• Positive control: Cell lines or tissues known to express RPS11 (e.g., HepG2 cells for liver research)

• Negative control: Samples where primary antibody is omitted to assess non-specific binding of secondary antibodies

• Isotype control: Irrelevant antibody of the same isotype to evaluate background staining

• Dilution series: Of both antibody and antigen to establish sensitivity and dynamic range

• Cross-reactivity testing: With similar proteins to confirm specificity

Inter-slide reproducibility should be assessed using sequentially printed arrays with control lysates, with acceptable coefficient of variation (CV) being <10% . Between-run precision should be evaluated using multiple staining sessions of identical sequentially printed protein microarrays.

How does RPS11 expression correlate with clinical parameters in hepatocellular carcinoma?

Research has revealed significant correlations between RPS11 expression levels and clinical parameters in HCC patients. The following table summarizes key findings from a training cohort of 182 HCC patients:

These findings were validated in a second cohort of 90 HCC patients:

Notably, high RPS11 expression levels were significantly associated with elevated alpha-fetoprotein (AFP) levels in both cohorts (P=0.021 and P=0.010, respectively) . Additional correlations were found with elevated CA19-9 levels (P=0.002), elevated ALP levels (P=0.003), and poor tumor differentiation (P=0.022) in the training cohort.

How can RPS11 antibody-based assays be integrated into prognostic models for cancer?

RPS11 antibody-based assays can be integrated into prognostic models by:

• Establishing standardized cutoff values for RPS11 expression levels (e.g., H-score thresholds) to classify patients into high and low expression groups

• Combining RPS11 expression data with other significant clinical parameters (AFP levels, tumor size, etc.) through multivariate analysis

• Developing prognostic nomograms that incorporate RPS11 expression with other independent predictors to achieve more accurate survival and recurrence predictions

Research has demonstrated that integrating RPS11 expression data with other clinical variables improves prognostic accuracy for HCC patients after hepatectomy . When developing such models, researchers should validate their findings in independent cohorts to ensure reliability and generalizability.

What are the technical challenges in developing epitope-specific RPS11 antibodies?

Developing epitope-specific RPS11 antibodies presents several technical challenges:

• Selecting optimal antigenic regions: Similar to the challenges faced with RPS4Y1 antibody development, identifying regions with sufficient uniqueness is critical. Researchers must conduct careful amino acid sequence alignment to identify regions with highest specificity .

• Balancing epitope length: As demonstrated in RPS4 antibody development, inclusion of even a single extra residue can significantly impact protein stability while still preserving antigenicity, whereas longer sequences might completely abrogate antibody recognition .

• Isotype considerations: Different isotypes (IgG, IgM, IgA) may recognize the same epitope with varying affinities, which can lead to significant differences in detection sensitivity. As observed with other antibodies, the IgM response may be a statistical outlier for certain epitopes (p<1x10-7) .

• Validation across multiple methods: Confirming specificity requires multiple methodological approaches, including Western blotting, immunoprecipitation, immunohistochemistry, and flow cytometry, with appropriate positive and negative controls.

How does RPS11 antibody performance compare between recombinant and hybridoma-derived production methods?

Modern recombinant RPS11 antibodies offer several advantages over traditional hybridoma-derived antibodies:

• Increased sensitivity: Recombinant antibodies often demonstrate superior sensitivity in detecting low abundance targets

• Confirmed specificity: The defined sequence of recombinant antibodies ensures consistency in epitope recognition

• High repeatability: Batch-to-batch variation is minimized

• Sustainability: Production doesn't rely on animal immunization, allowing for consistent supply

• Animal-free production: Aligns with ethical considerations in research

What methodological adaptations are needed when using RPS11 antibodies in blood-contaminated tissue samples?

When working with blood-contaminated tissue samples, several methodological adaptations are necessary:

• RBC protein control: Include red blood cell (RBC) protein lysate as a control sample to identify proteins that are positive in the RBC sample and may confound results

• RBC-specific marker: Use an antibody against a specific RBC protein to measure the relative intensity of RBC contamination in each sample

• ssDNA normalization: Single-stranded DNA is proportional to total non-red blood cell content and can serve as a suitable normalization parameter for blood-contaminated samples

• Sample preparation optimization: For peripheral blood mononuclear cell (PBMC) preparations, consider additional purification steps to reduce contamination from immunoglobulins, albumin, and other abundant proteins

These adaptations help ensure that RPS11 antibody signals accurately reflect target protein abundance rather than artifacts from blood contamination.